![biorad1](http://www.americanbiotechnologist.com/blog/wp-content/uploads/2012/06/biorad_logo.png?w=128&h=36" "biorad1"){kind=logo}
For some reason, I just can’t get the “Eye of the Tiger” song out of my head! Gotta love this:
Now that you’re in the mood, how about taking a look at another epic battle!
Posts Tagged ‘Bio-Rad Laboratories’
Battle of the Blotters
:: Posted by American Biotechnologist on 11-26-2012
Pathway Curation and Real-Time PCR Panel Design Strategy
:: Posted by American Biotechnologist on 11-20-2012Pathway analysis provides an efficient and focused approach for studying a large number of related gene targets in a single experiment. The pathway curation and ranking strategy employed by Thomson Reuters and Bio-Rad ensures that the gene assays present on each real-time PCR pathway and collection panel are the most relevant for gene expression profiling based on differential expression studies and the frequency with which gene targets appear in the peer-reviewed literature. All PrimePCR assays were designed following strict guidelines on maximum transcript coverage, have minimal overlap with known single nucleotide polymorphisms, and span large introns where possible. In addition, they have all been fully validated in the lab, passing stringent quality controls. As a result, PrimePCR panels set a new quality standard for commercially available predesigned qPCR pathway panels.
Click here to read the full article in Bioradiations.
Click on the pathway map below to view a larger version.
Apoptosis and survival — TNF-R1 signaling pathway map. This pathway map is one example of the 260 canonical pathway maps provided by Thomson Reuters. Pathway maps illustrate protein interactions and regulation to provide a comprehensive picture of signaling and disease processes. On the Bio-Rad website, each target on the map can be selected to view corresponding gene and protein information.
Bio-Rad Receives Award in Quantitative and Digital PCR Instrumentation
:: Posted by American Biotechnologist on 11-19-2012Bio-Rad Laboratories, Inc. announced it has received the Frost & Sullivan 2012 North American Market Penetration Leadership Award in Quantitative and Digital PCR Instrumentation. This annual award honors the company that has demonstrated excellence by growing market share at the fastest rate in its industry, as measured by revenues or units sold.
Frost & Sullivan, a global growth consulting company, cited findings from its best practices research that show Bio-Rad has built a solid reputation in amplification technologies. According to Frost & Sullivan’s research, Bio-Rad continually releases innovative products to earn customer loyalty and gain market share, with particularly strong market positions in both the real-time PCR (qPCR) and digital (dPCR) instrumentation markets.
“Bio-Rad clearly exhibits some of the key traits shared by the most successful companies: the ability to locate and solve unmet needs in the markets they serve and a dedication to continuous R&D,” said Christi Bird, life sciences senior industry analyst at Frost & Sullivan. “Bio-Rad’s commitment to innovation, coupled with its keen focus on other qualities valued most by its customers, has resulted in a strong and growing market position that makes the company an ideal recipient of this year’s Frost & Sullivan Market Penetration Leadership Award.”
“We are honored to receive recognition of our leadership in the real-time and digital PCR markets,” said Rachel Scott, amplification instruments business unit marketing manager at Bio-Rad. “The Frost & Sullivan award is a reflection of how we strive to develop innovative new solutions that align with the needs of the research community in terms of both technology and pricing.”
Frost & Sullivan expects Bio-Rad to continue its market share gains in qPCR with several instruments launched in 2011, including the CFX96 Touch™ and CFX Connect™ real-time PCR detection systems.
In the dPCR market, Frost & Sullivan believes the QX100™ Droplet Digital™ PCR system holds the greatest promise of all dPCR instruments currently on the market, due to its simplicity, performance, and affordability. The QX100 system has already received significant attention from pharmaceutical companies and cancer research laboratories, leading Frost & Sullivan to believe that the instrument will be the early market leader in the expanding dPCR market.
“Bio-Rad has also seen a great deal of interest from the growing molecular diagnostic market,” said James Lee, Droplet Digital PCR commercialization marketing manager at Bio-Rad. “We plan to participate in this market in the near future using our ddPCR™ technology.”
Bio-Rad was honored with this recognition at Frost & Sullivan’s 2012 Excellence in Best Practices Awards Banquet on November 8 in San Antonio, Texas. The event highlighted companies, strategies, processes, and executives that have achieved world-class performance within their industries.
For more information about Bio-Rad’s PCR products, visit http://bit.ly/PCR_Products.
Chemiluminescence, Multiplex Fluorescence and Routine Gel Imaging All In One
:: Posted by American Biotechnologist on 11-13-2012TGX Stain-Free™ Precast Gels Facilitate LDL Research on Potential New Drug Targets
:: Posted by American Biotechnologist on 10-24-2012Cholesterol is a waxy fat produced in the human body that is associated with both low-density lipoproteins (LDLs) and high-density lipoproteins (HDLs). Due to genetic predisposition and lifestyle factors such as diet and exercise habits, LDL-associated cholesterol (LDL-C), the “bad” form of cholesterol, can accumulate on arterial walls and harden to form a plaque, causing a narrowing and loss of elasticity in these blood vessels. This process, known as atherosclerosis, or hardening of the arteries, increases the risk of cardiovascular diseases like heart attack and stroke.
Dr Frederick Bauzon, a postdoctoral researcher in Dr Ronald Krauss’s lab at the Children’s Hospital Oakland Research Institute (CHORI), is investigating the role of a candidate gene associated with HMGCR transcript levels discovered in a linkage study. The gene expression levels are “reduced” using a small interfering RNA (siRNA) and the effects on expression of the low-density lipoprotein receptor protein (LDLR) are examined. The established mechanism is that reducing LDLR expression decreases the amount of available receptor protein, which normally binds LDLs circulating in the bloodstream and transports them back inside the cell. The pathway was discovered ~20 years ago and has been of interest in drug target development due to its regulating role.